ERAS 3490
Alternative Names: ERAS-3490Latest Information Update: 13 Jun 2023
At a glance
- Originator The Regents of the University of California
- Developer Erasca
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 15 May 2023 Erasca plans phase-I AURORAS-1 trial for Non-small cell lung cancer before 2024
- 31 Dec 2022 Erasca has pending PCT patent applications for KRAS G12C inhibitors, their preparation and method of use worldwide
- 31 Dec 2022 Erasca has pending US non-provisional patent applications for KRAS G12C inhibitors, their preparation and method of use in US